INTRODUCTION
The advent of newer technologies enables exploration of the human microbiome. The human microbiome or microbiota is the collection of microorganisms that live in and on the human body 1 . In an individual, microbial cells outnumber human cells by a factor of 100 in some estimates, but recent estimates conclude an equal number of microbial and human cells 2 , with microbial genes outnumbering human genes by a factor of 100 3 . This lopsided ratio has important ramifications, including supporting the hologenome theory which asserts the human microbiome likely co-evolved with its human hosts, as there is evidence that it provides metabolic pathways that human cells do not have 4 . The complex amalgamation of microbiota in human microenvironments provide for symbiotic interactions necessary for human health 5 . Dysbiosis, or the disruption of the microbiome and its related collection of genes, or metagenome can lead to disease since the metagenome is a unique juxtaposition of genomics and environment, providing both unique metabolic functions and micro-environmental stimuli for the human host 6 . The human microbiome project (HMP) undertaken in 2007 7 was initially designed to understand the "normal" microbiome across the human lifespan, and to understand the significance of the microbiome in human health and disease. Subsequently, studies have been investigating the various human microbiota in disease.
THE HUMAN MICROBIOME CAN BE READILY CHARACTERIZED WITH NEW GENETIC SEQUENCING TECHNOLOGY
The advent of massive parallel sequencing of the polymerase chain reaction (PCR) products or amplicons enables high throughput determination of the microbial ecology in a biological sample and categorization of metagenomes in a human habitat 8 . It is now known that less than 1% of bacteria collected from soil that are seen under the microscope form colonies on culture, and only 50% of bacteria sampled from human sites identified by 16S ribosomal ribonucleic nucleic acid (RNA or rRNA) sequencing techniques are recovered by traditional culture techniques 9, 10 . A common method to characterize microbiome is sequencing deoxyribonucleic acid (DNA) of the RNA component of the 16S rRNA gene, a highly conserved bacterial gene 11 . It has conserved sequences to allow cloning with specific PCR primers 12 , but sequencing several of the nine hyper-variable regions of the RNA component of the 16S rRNA gene, designated V1 to V9 allows identification of bacteria at the genus level (16S rRNA gene sequencing) 12 . Not one hypervariable region can differentiate amongst all bacteria, however the V1-V3 region distinguishes nearly all bacteria considered pathogenic at the genus level, except for the Enterobacteriaceae genus 13 . An advantage of the genetic sequencing methods as opposed to traditional culture methods is the avoidance of over-representation of easily cultured bacteria over bacteria that is difficult to culture. A recent microbiome study reveals that Haemophilus and Moraxella genera are detected more frequently with the novel genetic techniques versus traditional culture methods, while the presence of Enterobacteriaceae is overestimated since it is easier to detect Enterobacteriaceae versus Haemophilus and Moraxella by conventional culture 14 . To classify different taxa of bacteria by 16S rRNA gene sequence data, the similarity of the sample sequences is compared to a known taxonomic data set, using a 97% similarity threshold, sequences are then grouped into operational taxonomic units (OTU), since the bacterial species associated with a specific genetic sequence may not be known 4 .
16S rRNA gene sequencing provides descriptive assessment of taxonomic compositions and phylogenetic diversity of microbiomes, but does not distinguish the metabolic capabilities of the microbiome. Whole genome sequencing of the microbiome or metagenomic sequencing identifies the genes which underlie the collective metabolic and functional capacity of a microbiome 15 . Metagenomic sequencing had entailed time-consuming, costly and data-intensive sequencing (via Sanger sequencing method) of the entire set of genes in microbiome habitat. Though this has been simplified with the use of massively parallelized sequencing, it still involves complicated post-sequencing methods to avoid analysis of human DNA in addition to microbial DNA 16 . Recently developed bioinformatics software can infer the metabolic pathways of a metagenome given the sample's taxonomic composition 17 .
After a microbiome's taxonomic composition is detailed, the characteristic parameters can be determined. These include the number of unique taxonomic units detected in a sample (community richness), the relative numbers of taxonomic units in a sample (evenness), the diversity of a sample with either a measure of the richness and evenness within a sample (alpha diversity, e.g. Shannon Index), and/or the similarity of the bacterial composition between samples, (beta diversity, e.g. Brays-Curtis or UniFrac) 18 (Table 1) .
THERE IS A LUNG MICROBIOME IN HEALTHY INDIVIDUALS
It was believed that the lungs are sterile in healthy humans 19 and the lungs were excluded in initial HMP studies. However, the belief was based on data using traditional culture techniques. The first report, by Hilty et al. 20 , utilizing genetic sequencing techniques, revealed a lower airways microbiome in healthy humans, compared the microbiome of three cohorts with either asthma, chronic obstructive pulmonary disease (COPD) or healthy controls. The microbiome of nasal cavity and oropharynx sampled by surface swabs and that of the lower airways sampled via bronchial brushing of the mucosal surface of the left upper lung lobe were compared in the study. Sequencing of the microbiome in the bronchial brushings of the control subjects (n = 8), identified multiple bacterial phyla. Additionally, bacterial abundance in the range of 1-10 million bacterial cells/sample was similar in the three groups, but there were significant differences in microbiome composition amongst the groups.
An abundant microbiome in the healthy lung was met initially with disbelief 21 . One concern was that the lower airway microbiome results could be confounded by upper airway contamination, since the oropharynx has a bacterial load several orders of magnitude higher than that of the lower airways. Furthermore, even sterilized reagents and fluids used in the sampling and processing procedures could contain DNA from dead bacteria detectable with 16S rRNA gene sequencing. Adequate negative controls are required in order to control and account for such environmental contamination, which were not performed in this study. The next published study by Erb-Downward et al. 22 also showed a similarly abundant microbiome in healthy human airways sampled by bronchoalveolar lavage (BAL); however, the same limitations applied to this study.
To address the concern of upper airway contamination of lower airway sampling, Charlson et al. 21 investigated the microbiome in both the upper and lower respiratory tract in six healthy individuals employing double bronchoscope sampling ( Fig. 1) , a technique developed by our group for conventional microbiology studies of the lower airway microbiome. In this technique, the upper and lower airways are anesthetized with one scope, and subsequently a second scope with an unused and therefore uncontaminated channel is used to obtain bronchial brushings and lavage 23 . Inclusion of control measurements of reagents and saline washes of bronchoscopes prior to sampling characterized the contribution of environmental contamination to the observed lower airways microbiome. Congruent with published studies, the lower airway samples had microbiota; however, the bacterial counts were much lower, in the range of 100-10,000. Low levels of bacterial DNA were seen in control samples, but these were in the range of 10-100 bacteria/ml. Comparison of the oropharyngeal swab and the bronchial brushings microbiome discovered a distinctly less abundant microbiome in the lower respiratory tract compared to the upper respiratory tract. There was more diversity and representation of bacterial lineages in the lower airways versus the upper respiratory tract. Although several unique OTUs were found only in the lower respiratory tract versus the upper respiratory tract, none were shared amongst different subjects.
Subsequent studies have supported the observations of Charlson et al. 21 , and now there is consensus that there is a healthy lung microbiome, albeit relatively sparse in comparison to that of the upper airway. It is likely that the healthy human lung microbiome represents transitory presence of micro-aspirated upper airway microbial flora that is in the process of being cleared by normal lung defence mechanisms 24 . The acronym TBNR, which represents 'transient but not resident' appears to be a fairly accurate characterization of the healthy lung microbiome 25 . 
TO FURTHER CHANGES IN THE LUNG MICROBIOME
In contrast to the "sterile" healthy lung, COPD airways often contain bacteria, including potential respiratory pathogens based on previous traditional culture based studies of the lower respiratory tract in stable COPD 23, 26 . Furthermore, this bacterial milieu is associated with inflammatory responses, radiological changes of bronchiectasis, pathological changes of a local immune response and increased daily COPD related symptoms 27 . These observations support the vicious circle hypothesis (Fig. 2 ) 28 . The vicious circle hypothesis proposes that alterations in innate lung defence induced by inhalational exposure due to tobacco smoke or biomass smoke allow particular pathogenic bacteria that normally enter the lower respiratory tract with other commensal organisms by micro-aspiration, to persevere and flourish. These bacteria, signalling through various pathogen recognition receptors on airway epithelial and immune cells, induce inflammation, which represents an attempt by the lung to clear the infection. However, the inflammation induces further damage to innate lung defence mechanisms, allowing further bacterial persistence and proliferation and thus establishing the vicious circle. This circle of chronic infection and inflammation contributes to the progressive lung damage and loss of function that is characteristic of COPD, often even after the primary insult (e.g. tobacco smoke) is removed 29 . Improvements in molecular characterization of bacteria and studies of host immunological responses to these pathogens led to the establishment of another important role of bacteria in COPD, as a cause of about 50% of exacerbations 28 .
The vicious circle hypothesis as described above has focused on well-described potential respiratory pathogens as the major drivers of disease. Given our increasing knowledge of lung microbiomes in healthy and diseased lungs the vicious circle hypothesis has been revised ( Fig. 2 ). Insults such as tobacco smoke that impair innate immune defences lead to changes in the abundance, taxonomic composition and/or phylogenetic diversity of the lung microbiome. This microbiome imbalance or dysbiosis leads to maladaptive inflammatory responses, further impairment of lung defences and further derangements of the lung microbiome, setting up the vicious circle with its attendant consequences. Substantial acute changes in the airway microbiome, for example by introduction of a new strain of a respiratory pathogen, lead to larger inflammatory responses, which present clinically as exacerbations of COPD. It is likely the contribution of the vicious circle to COPD progression and pathogenesis varies among individuals, with a larger contribution in those individuals with a greater deviance from normal in their innate immune defences and/ or the inflammatory response to the microbiome.
Supportive evidence for the vicious circle hypothesis and bacterial exacerbation mechanisms based on conventional culture techniques has been reviewed in earlier publications 27, 28 . Below we will discuss studies using microbiome techniques examining this hypothesis 30 .
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CHANGES IN COPD MICROBIOME BECAUSE OF THE ALTERED LUNG MILIEU
One prevalent theme in the evaluation of the human microbiome is that different human anatomic locations constitute different "islands" of habitation and differ in time and location, as described in the island biogeography theory 7 . However, a countervailing theory based on topological continuity of the airways asserts that the different habitats in the human respiratory tract from the nasal and oral cavities to upper and lower airways are contiguous and bacteria in the lower airway would be indistinguishable from the upper airway bacteria 31 .
Studies in healthy controls support the topological continuity theory as shown by Charlson et al. 21 and recently by Bassis et al. 32 In the latter study, the microbiome from the oral cavity, nasal cavity, both lungs and the stomach from 28 healthy subjects were compared to determine the contribution to the microbiome of the lower aerodigestive sites from the upper sites [32] [33] [34] . They found that the nasal cavity microbiome is distinct, however, the mouth was a major source of the microbiome community members of the gastric and BAL microbiome.
In contrast to the healthy lung microbiome which is similar to the oral microbiome, studies describe disparate upper and lower airway Figure 2 . The vicious cycle in chronic obstructive pulmonary disease (COPD) pathogenesis. After the initial insult impairs innate lung defence, changes in the microbiome perpetuates a cyclical sequence of events that contributes to the persistent inflammation and microbiome changes that are characteristic of COPD (reproduced with permission from Sethi S et al. 28 ).
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microbiomes in COPD which supports the substantial influence of the lung micro-environment on the microbiome in COPD. Though the microbiome is likely initially derived from the upper airway in COPD, there must be substantial changes in its composition from interactions with the disease induced local micro-environment. Furthermore, this local micro-environment likely differs from the lung heterogeneity characteristic of COPD, resulting in corresponding variation in the microbiome. Such variability has been described by Cabrera-Rubio et al. 35 , when they compared sputum, bronchial aspirate, BAL and bronchial mucosa biopsy microbiomes in six subjects with moderate COPD. The bronchial aspirate and sputum microbiomes were distinct from the lavage and bronchial mucosa biopsy microbiomes, which were similar to each other. In the approximately 4-8 airway sites per lobe sampled within six explanted lungs from patients with severe COPD, Erb-Downward et al. 22 found significant heterogeneity driven by variable dominance of Pseudomonas, Haemophilus, or Stenotrophomonas genera.
The lung tissue microbiome from multiple sites of surgically resected lungs from non-smokers, smokers, very severe COPD and cystic fibrosis (CF) (n = 8 in each group) was studied by Sze et al. 36 , and they found a sparse microbiome in all the lung tissue samples. The COPD samples did not differ in bacterial abundance from the non-smoker and smoker control samples, but did differ in composition.
COPD SEVERITY IS INVERSELY RELATED TO MICROBIOME DIVERSITY
Reduced diversity with increasing severity of COPD was observed by Garcia-Nuñez et al. 39 , in their investigation of the sputum microbiome in moderate to severe versus very severe COPD. Galiana et al. 37 found diminished sputum microbiome alpha diversity in severe COPD (n = 10) compared to moderate to severe disease (n = 9), with overrepresentation of the Actinomyces genus in the latter group. In order to determine whether colonization with Pseudomonas aeruginosa altered the sputum microbiome of COPD, during stable disease as well as during exacerbations, Millares et al. 38 studied sixteen individuals with severe or very severe COPD. The subjects were grouped into those with (n = 5) and those without (n = 11) Pseudomonas aeruginosa colonization. Interestingly, biodiversity and other community characteristics of the microbiome were not different in the two groups during stable disease and exacerbation.
The observation in COPD of decreasing microbiome diversity associated with increasing disease severity parallels observations in other chronic airway diseases such as bronchiectasis and CF. While introduction of Pseudomonas aeruginosa does not cause alteration of microbiome diversity in COPD, it has been associated with adverse long-term outcomes in COPD.
It is yet to be determined whether reduced diversity is related to other clinical COPD attributes such as increased inflammation, frequent exacerbations and disease progression 39 .
AIRWAYS MICROBIOME CHANGES WITH ONSET AND TREATMENT 41 . In the study, two sputum samples were collected prior to the exacerbation, one collected when the patient presented with the exacerbation but before treatment, and two samples collected after the exacerbation were clinically resolved 23, 28, 42 . Microbial DNA from sputum samples were hybridized to a DNA microarray 43 . The two samples from pre-exacerbation stable disease had similar microbiomes within the same patient, suggesting short-term stability of the microbiome in stable COPD. During AECOPD, no changes in community richness, evenness and diversity of the sampled microbiome were observed. Nevertheless, substantial taxonomic composition variations were associated with an increase in Proteobacteria and a decrease in Actinobacteria, Clostridia, and Bacteroidia. Also, when known pathogens such as Haemophilus influenzae increased during AECOPD, closely related bacterial taxa in the phylogenetic tree were also enriched, while those taxa that were phylogenetically distant declined. These findings suggest enrichment of taxa closely related to a dominant pathogen could contribute to AECOPD pathogenesis.
OF COPD EXACERBATION
Systematically collected post-exacerbation samples provided an opportunity to assess treatment effects on the COPD airway microbiome. There was increased bacterial abundance in these post-exacerbation samples with only oral steroid treatment of the exacerbation, with enrichment of many taxa including members of Proteobacteria, Bacteroidetes, and Firmicutes. In contrast, individuals treated only with antibiotics reduced bacterial abundance, specifically Proteobacteria members. After both steroids and antibiotics were employed during an AECOPD treatment regimen, a variegated effect on the airway microbiome was seen (Fig. 3 ).
Similar findings of microbiome variations with exacerbation was observed with an experimental human model of rhinovirus-induced AECOPD, by Molyneaux et al. 44 where rhinovirus was inoculated intranasally in 31 human subjects (control subjects = 17, Moderate COPD subjects = 14). The sputum was collected prior (Day 0) and 5, 15, and 42 days after rhinovirus inoculation, in which rhinovirus levels, the microbiome, bacterial abundance and inflammatory parameters were assessed. In the COPD group, bacterial abundance was significantly increased from baseline, but not in the control group, and this increase correlated with elevated neutrophil concentration and neutrophil elastase levels. As opposed to no significant microbiome changes in the control group, the COPD group had significant microbiome composition dysbiosis, with a decline in or decreased (upper left quadrant) in the pairwise comparisons indicated, using moderated t-test models (R package limma). Results shown are from analyses of all subjects. Dashed lines, significant false discovery rate adjusted P values and changes in relative abundance of at least 2-fold, or log2 equal to 1. Taxa exhibiting significant changes are coloured by phylumlevel classification, as shown. Note that in addition to the highlighted taxa, many other microbiota members exhibited smaller-scale changes in abundance, which cumulatively may contribute importantly to microbiome community function. B: Changes in the relative abundance of taxa from exacerbation (exac) to Post1 and Post1 to Post2, segregated by type of exacerbation treatment (antibiotics only, systemic corticosteroids only, or both; n 4 subjects in each treatment group) (reproduced with permission from Huang YJ et al. 41 ). Haemophilus and a 9.5% increase in Neisseriaceae.
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LUNG MICROBIOME DIVERSITY AND RICHNESS DECLINE WAS ASSOCIATED WITH GREATER EMPHYSEMA AND GREATER IMMUNE CELL INFILTRATION
The vicious circle hypothesis suggests that the host immune response to the microbiome dysbiosis is maladaptive and contributes to progression of COPD. Evidence supporting the process utilizing new sequencing techniques studying the airways microbiome was published recently. In an innovative study, Sze et al. 45 examined the microbiome of five lungs from subjects with GOLD grade 4 (very severe airflow obstruction) disease, and four healthy donor lungs not used for transplantation. Alveolar destruction was quantified by measuring alveolar surface area of the tissue samples imaged by computed tomography (CT) scan and correlated to immunohistochemistry of histological lung tissue sections quantifying the immune cells. The relationship between microbiota, inflammatory immune cell infiltration and alveolar destruction was analysed by correlating the microbiome, immunohistological and CT scan data. Declining microbiome diversity and richness was associated with increased alveolar destruction and greater CD4 cell infiltration. Expansion of Proteobacteria and Actinobacteria phyla distinguishes the COPD group from the control group, while Bacteroidetes and Firmicutes had a greater representation in control lungs versus the COPD lungs. These observations suggest that changes in the microbiome, specifically increases in Proteobacteria and Actinobacter phyla drive the progression of COPD.
CYSTIC FIBROSIS
CF is regarded as the prototypical lung disease that is driven by chronic bacterial infection. This has prompted multiple microbiome studies to understand the role the airways microbiome in CF airways.
DYSBIOSIS IN THE AIRWAY MICROBIOME IS PREVALENT IN CF AND CHANGES WITH AGE
Sibley et al. 46 . initial study examining the microbiome in CF airways revealed a complex airway microbiome with 16s rRNA gene sequencing, and 46% of the bacterial groups identified in the samples were comprised of obligate anaerobes 46 . A microbiome analysis of the different areas of lung tissue obtained from a lobectomy performed on a 3-year-old CF patient revealed a spatial variation in the composition of the microbiota 47 . A 16S rRNA PCR amplification coupled with a rRNA microarray, the G3 Phylochip Array, was used to analyse BAL and oropharyngeal swabs from 13 children with CF and 9 children without CF 48 . The CF cohort had increased diversity and increased abundance of Prevotella veroralis, CW040 and a Corynebacterium compared to the non-CF cohort, indicating a disruption of the CF respiratory microbiome early in life.
In a relatively large study, An Italian study by Bacci et al. 50 compared the sputum microbiome in CF patients with a substantial decline in lung function to those in whom the lung function remained stable. Decreased microbial diversity was seen in the group with substantial decline in lung function, while an increase in Staphylococcus was seen in the stable group.
In summary, the lung microbiome is disrupted in CF early in life, and changes in structure and composition with age and progression of disease.
AIRWAYS MICROBIOME IN CF EXACERBATIONS
Though several studies have examined changes in the airway microbiome with CF exacerbations, the findings have been inconsistent. When Fodor et al. 51 examined the microbiome of 23 adult CF patients in expectorated sputum and oral wash samples obtained during acute exacerbation, after antibiotic treatment, and during stable disease, they found that 60% of the sequences were from Pseudomonas and Burkholderia. However, the microbial composition was similar in the three sample collection time periods, indicating that exacerbations in CF were not related to acute changes in the airways microbiome.
On the other hand, when Carmody et al. 52 explored the microbiome of 68 paired sputum samples at baseline and during exacerbation from 28 CF patients, the abundance of the Gemella bacterial genus was increased during exacerbation compared to baseline samples. Reid et al. 53 microbiome analysis of sputum from CF patients with pulmonary exacerbation compared to CF patients without exacerbation revealed an alteration of the anaerobic bacterial population, particularly an increase of the Chrysiogenales genus, which was also associated with elevated levels of anaerobic metabolites: pyruvate, lactate and putrescine.
A subsequent metagenomics analysis of CF sputum samples collected longitudinally amongst three patients before, after and during exacerbation reveals unique diverse microbiota composition that changes over time 54 . The microbiota corresponding to the different individuals were associated with variable microbial metabolic potentials and dynamic antibiotic resistance profiles.
CHANGES IN CF MICROBIOME WITH THERAPY
On 16S gene sequencing of CF sputum samples collected during a pulmonary exacerbation at three time points (before intravenous antibiotic administration, at day 3 of intravenous antibiotic administration, and day 8-10 day of intravenous antibiotics) from 23 individuals, bacterial composition was the same before and after treatment. However, there was a decrease in Pseudomonas abundance with a transient increase in microbial diversity on day 3, that dissipates by the second week of intravenous antibiotics 55 .
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Oral supplementation with Ferrous sulphate in a randomized, double-blind, trial in CF patients did not change the diversity of the microbiome nor the abundance of pathogenic genera, Pseudomonas, Staphylococcus, Haemophilus, Rothia and Achromobacter 56 . This finding allays the concern that supplemental iron could cause pulmonary exacerbations or increase Pseudomonas abundance 57 .
A therapy targeted against the CF transmembrane conductance regulator (CFTR) G551D mutation, Ivacaftor, has improved FEV1 in selected CF populations, and was shown to alter the sputum microbiome analysed with a statistically significant increase in Porphyromonas and significant decrease of Streptococcus bacteria 58 .
NEW APPROACHES IN CF AIRWAYS MICROBIOME CHARACTERIZATION
The first metagenomics analysis of CF sputum samples from two individuals aged 14 and 17, revealed high abundances of Haemophilus, Staphylococcus and Streptococcus species, with relatively few fungal species identified 59 . A metagenomics and metatranscriptomic (RNA sequencing) analysis of CF sputum samples conducted by Quinn et al. 60 , revealed the microbiota had significant enrichment of amino acid metabolism, folate biosynthesis and lipoic acid biosynthesis. Further analysis of the metabolism of the microbiota may allow for novel therapeutics targeted against essential metabolic pathways of the CF microbiome.
A study by Kim et al 61 . utilized high-throughput sequencing of the ribosomal RNA internal transcribed spacer 1 (ITS1), a common method to sequence fungal communities, and found that Candida and Aspergillus species were the dominant fungi in CF sputum samples.
In summary, lung microbiome changes can be seen early in life in CF, with further changes associated with age, disease progression and treatment. The impact of these changes in the microbiome on the manifestations and course of this disease are still to be understood.
NON-CF BRONCHIECTASIS (NCFB)
Though there is longstanding recognition of the role of the lung microbial flora in driving structural changes in the lung, such as bronchiectasis, as described in the vicious circle hypothesis, there has only been limited exploration of the microbiome in bronchiectasis.
AIRWAY MICROBIOME IN NCFB
Conventional microbiology studies, such as the one by McDonnell et al. 62 , had revealed a diverse microbial flora in sputum samples from patients with NCFB 62 . The specific focus of these studies was usually aerobic flora and conventional respiratory pathogens. Though Haemophilus influenzae was often the most common pathogen isolated, the isolation of Pseudomonas aeruginosa was associated with worse lung function and clinical outcomes. When Rogers et al. 63 applied 16s microbiome sequencing methods to characterize sputum samples from NCFB patients, they found that along with H. influenzae and P. aeruginosa, Veillonella, Prevotella, Streptococcus and Neisseria were also often the dominant taxa 63 . Increased microbiota diversity was associated with better lung BARCELONA RESPIRATORY NETWORK function and less airway and systemic inflammation, while these measures were worse when any taxa was dominant.
EFFECT OF TREATMENT AND EXACERBATIONS ON THE AIRWAY MICROBIOME IN NCFB
Macrolide antibiotics are often used to prevent exacerbations of NCFB. The effect of such treatment on the sputum microbiome was examined by Rogers et al. 64, 65 in the BLESS trial with Bronchiectasis and low dose erythromycin (BLESS trial: ACTRN12608000460303) trial, where they had access to 44 samples before and after erythromycin treatment for 12 months, and 43 control samples where patients received placebo. A worrisome emergence of P. aeruginosa was seen only in the erythromycin group if their baseline samples did not contain this pathogen.
In a striking similarity to descriptions in COPD and CF, there were no major changes in the airway microbiome community structure with exacerbation 66 , though this study was limited in power. Changes in composition of the microbiome at exacerbation were seen, and larger studies are needed to better characterize the impact of exacerbations and their treatment on the microbiome in NCFB.
ASTHMA
The complexity of asthma phenotypes and endotypes is now well recognized, and several investigations have examined for associated changes in the lung microbiome. Insights in to the role of upper airway and gut microbiomes early in life in determining the emergence of asthma have grown and are discussed below.
AIRWAYS MICROBIOME DIFFERS IN ASTHMA AND HAS FUNCTIONAL CORRELATIONS
The first study in asthma by Hilty et al. 20 study using 16S rRNA based PCR amplicon analysis revealed that asthmatic airways had reduced Bacteriodetes (particularly Prevotella) and increased Proteobacteria (particularly Haemophilus) compared to controls. However, this study had methodological limitations as discussed above.
Huang et al. examined adult asthmatics and healthy controls who underwent bronchial epithelial brushings during a study examining macrolide therapy to reduce airway bacteria to improve asthma control. Asthmatic subjects had greater microbial diversity than controls, and bronchial hyperresponsiveness was inversely correlated to bacterial diversity in the asthmatic cohort 67 . The relative abundance of particular bacterial families of the Proteobacteria phylum, members of the Comamonadaceae, Sphingomonadaceae, Oxalobacteraceae, correlated with the degree of bronchial hyperresponsiveness. Marri et al. 68 , showed different microbiome composition between asthmatic and non-asthmatic adults utilizing 16S rRNA gene sequencing of DNA extracted from induced sputum. Increased Proteobacteria and lower Firmicutes and Actinobacteria proportions in the asthmatic airways compared to the health controls were seen. asthmatic and non-asthmatic participants of the Asthma Severity Modifying Polymorphisms (AsthMaP) project suggests that asthma nasal microbiome is less diverse than healthy controls 69 . In this study there were more Proteobacteria and less Firmicutes in the asthmatic nasal microbiome, and a dominance of the Proteobacterium, Moraxella catarrhalis in the asthmatic samples. A secondary analysis of the microbe-host interactions found an increased expression of microbiome adhesion genes. Furthermore, the presence of Proteobacteria was positively associated with an upregulation of a host pro-inflammatory cytokine, IL-1α, suggesting compositional changes in the microbiome can lead to functional changes that modulate the host inflammatory response 70 .
Alterations in the microbiome with the severity and control of asthma have now been described. In a recent study by Huang et al. 71 bronchial brushings revealed dysbiosis of the airways microbiome in severe and mild-moderate asthmatics, when compared to healthy controls. Proteobacteria were associated with worse asthma control, while Actinobacteria was an indicator of steroid responsiveness. Zhang et al. 72 examined the induced sputum microbiome in 26 severe asthmatic, 18 mild-moderate asthmatic, and 12 healthy adults and found that Proteobacteria was more common in mild-moderate asthma group while Bacteroidetes and Fusobacteria were reduced in the mild-moderate and severe asthma groups.
In summary, the airway microbiome is indeed altered in asthma and could have a role in determining airway hyper-responsiveness, airway inflammation, response to medications and the level of asthma control.
MICROBIOME EXPOSURE IN EARLY CHILDHOOD CONTRIBUTING TO ASTHMA PREDISPOSITION
The premise that sterile environments may predispose patients to asthma, while early childhood exposures to diverse microbial milieu prevents asthma acquisition, is the basis of the hygiene hypothesis 73 . The finding that greater microbial diversity is inversely related to airway hyper-responsiveness is congruent with the recent revision of the hygiene hypothesis that early life exposure to diverse microbes diminishes the risk of developing asthma 74 . A complementary theory, the infectious asthma hypothesis asserts decreased microbiome and exposure to specific pathogenic microbes early in life cause lung injury predisposing individuals to repeated airway damage and ultimately activates a strong Th2 immune response to environmental antigens 74 (Fig. 4) .
Evidence to support this revised hygiene hypothesis includes observations of the low incidence of asthma in Amish populations in the US, as in this farming community, childhood contact with farm animals exposes them diverse microbiota 73 . The Prevention of Allergy-Risk Factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle (PARSIFAL) and Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community (GABRIELA) study groups describe decreased rates of asthma in children growing up in farms in central Europe, compared to children located in the same region not living on farms. Furthermore, they found an inverse correlation between the probability of developing asthma and the number of bacteria and fungi groups detected via 16S rRNA and traditional BARCELONA RESPIRATORY NETWORK culture techniques in dust collected from the respective household 75 . In order to further understand the effect of the impact of the environmental microbial contact on the development of asthma, Stein et al. 76 studied two distinct, endogamous farming subgroups in the US, the Amish and Hutterites, two populations that are genetically more similar than other European populations. They have very similar lifestyles and risk factors for asthma, except the Amish use traditional farming methods, with frequent contact with farm animals, while the Hutterites live on highly mechanized communal farms. The Amish have a quarter of the incidence of asthma compared to the Hutterites (5 versus 21%). Dust collected via electrostatic dust collectors and mattresses from the Amish homes had endotoxin levels nearly seven times higher than the Hutterite homes. The microbial composition between the two groups was different with increased relative abundance of Bartonellaceae in the Amish sample compare to the Hutterite sample. When extracts of dust collected from 74 , Copyright (2015) , with permission from Elsevier).
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Collaborative research 118 BRN Rev. 2017;3 the floors of the living rooms of the ten homes from each community was administered intranasally to a murine ovalbumin model of allergic asthma, only the Amish dust prevented IgE elevation, airway eosinophilia and airway hyperresponsiveness.
INTERSTITIAL LUNG DISEASE
As with other chronic lung diseases, the airways microbiome in interstitial lung disease (ILD) has also been studied. However, one major confounder with the ILD airways is the heterogeneous prevalence of traction bronchiectasis, which could lead to changes in airway microbiome composition that are more a result of the fibrosis rather than a cause.
AIRWAYS MICROBIOME IS DIFFERENT IN ILD VERSUS HEALTH SUBJECTS
The COMET-IPF (Correlating Outcomes with biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis) investigators used principal component analysis of 16S rRNA gene sequencing of DNA extracted from BAL from individuals with idiopathic pulmonary fibrosis (IPF) to identify two OTU clusters associated with disease progression: Streptococcus and Staphylococcus 77 . A subsequently published, prospective study examined the BAL microbiome in 65 subjects with IPF compared to 44 healthy controls and 17 subjects with moderate COPD 78 . The BAL from IPF subjects had > 2 times the copies of 16S rRNA gene/ml, signifying larger bacterial loads than both control and COPD groups. However, there were no controls included to account for oral contamination. The bacterial burden in IPF was associated with a known host factor associated with developing IPF, the rs35705950 polymorphism in the promoter of the mucin gene MUC5B genotype, which has been implicated in bacterial clearance 79, 80 . Although diversity was not significantly different between the three groups, Haemophilus, Streptococcus, Neisseria, and Veillonella genera were more abundant in the IPF microbiome versus the control group. In contrast to these findings, Garzoni et al. 81 characterized the airway microbiome in BAL and oropharyngeal swabs in ILD and found no dysbiosis amongst their cohorts.
CONCLUSION
A sparse transient microbiome in healthy individuals that exhibits significant dysbiosis with the development of chronic lung disease is now firmly established. Further changes in the microbiome appear with a change in state from stable to exacerbation in chronic lung diseases. Imbalance of the airway microbiome may lead to maladaptive host responses that predispose individuals to chronic lung disease. We are only beginning to understand the functional implications of this dysbiosis and its contribution to disease progression, precipitation of exacerbations and impact on therapeutic interventions in chronic lung diseases 82 . Increasing application of new techniques such as whole genome sequencing and metatranscriptomics with larger cohorts sampled over longer time periods should provide us greater insights. Methodological advances in obtaining microbiome data have outpaced the development of robust and innovative tools to interpret the microbiome data.
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